Literature DB >> 9579739

Validation of Furchgott's method to determine agonist-dependent A1-adenosine receptor reserve in guinea-pig atrium.

T E Morey1, L Belardinelli, D M Dennis.   

Abstract

1. The ubiquitous distribution of A1-adenosine receptors (A1AdoR) represents an impediment to achieve organ and/or response selectivity of A1AdoR agonists. Differential receptor reserve may be exploited to overcome this problem. We hypothesize that A1AdoR reserve is agonist-dependent and can be accurately estimated with Furchgott's method. 2. Concentration-response curves were constructed from measurement of the atrial monophasic action potential duration in guinea-pig, isolated hearts treated with R(-) N6-(2-phenylisopropyl)adenosine (R-PIA) or 2-chloro-N6-cyclopentyl-adenosine (CCPA) before and after treatment with the selective, irreversible A1AdoR antagonist 8-cyclopentyl-3-[3-[[4-(fluorosulphonyl)benzoyl]oxy]propyl]-1-prop ylxanthine (FSCPX). Using Furchgott's method, we determined the equilibrium dissociation constant (KA) of R-PIA and CCPA, and the fraction of non-inactivated A1AdoRs remaining after FSCPX treatment (q(functional)). Values of q(functional) were correlated to the fraction of specific binding sites after FSCPX treatment labelled by [3H]-8-cyclopentyl-1,3-dipropylxanthine ([3H]-CPX) derived from saturation binding normalized to control (q(binding)). 3. Both R-PIA and CCPA are full A1AdoR agonists, but have significantly different potencies (pD2 [EC50]=6.84+/-0.04 [145 nM] vs 7.36+/-0.04 [44 nM], respectively), receptor affinities (pKA [KA]= 6.54+/-0.10 [288 nM] vs 6.13+/-0.03 [734 nM]), and pharmacological shift ratios defined as KA/EC50 (2.2+/-0.6 vs 15.9+/-1.5). Values for q(functional) and q(binding) were highly correlated (r2=0.96). The ratio between the intrinsic efficacies of CCPA and R-PIA derived from Furchgott's analysis was 5.9, a value similar to the ratio of 6.2-6.6 calculated from previously obtained binding data. 4. Radioligand binding studies validated the use of Furchgott's method to estimate A1AdoR reserve. A1AdoR reserve was agonist-dependent. CCPA was shown to be a high intrinsic efficacy, low affinity agonist, whereas R-PIA was found to be a low intrinsic efficacy, high affinity agonist.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579739      PMCID: PMC1565302          DOI: 10.1038/sj.bjp.0701747

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  Tonic activity of the rat adipocyte A1-adenosine receptor.

Authors:  Hui-Xiu Liang; Luiz Belardinelli; Mark J Ozeck; John C Shryock
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  A comparison of an A1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pig.

Authors:  S Snowdy; H X Liang; B Blackburn; R Lum; M Nelson; L Wang; J Pfister; B P Sharma; A Wolff; L Belardinelli
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells.

Authors:  S P Baker; P J Scammells; L Belardinelli
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors.

Authors:  A H Li; L Chang; X d Ji; N Melman; K A Jacobson
Journal:  Bioconjug Chem       Date:  1999 Jul-Aug       Impact factor: 4.774

5.  Experimental hypothyroidism modifies specific binding of A1 and A2A analogues to adenosine receptors in the rat kidney.

Authors:  Martha Franco; Othir Galicia; Alicia Quintana; Flavio Martínez
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

6.  A1 Adenosine Receptor-Mediated Inhibition of Parasympathetic Neuromuscular Transmission in Human and Murine Urinary Bladder.

Authors:  Timothy J Searl; Danuta I Dynda; Shaheen R Alanee; Ahmed M El-Zawahry; Kevin T McVary; Eugene M Silinsky
Journal:  J Pharmacol Exp Ther       Date:  2015-11-03       Impact factor: 4.030

7.  Methodical Challenges and a Possible Resolution in the Assessment of Receptor Reserve for Adenosine, an Agonist with Short Half-Life.

Authors:  Judit Zsuga; Tamas Erdei; Katalin Szabó; Nora Lampe; Csaba Papp; Akos Pinter; Andras Jozsef Szentmiklosi; Bela Juhasz; Zoltán Szilvássy; Rudolf Gesztelyi
Journal:  Molecules       Date:  2017-05-19       Impact factor: 4.411

Review 8.  Molecular probes for the human adenosine receptors.

Authors:  Xue Yang; Laura H Heitman; Adriaan P IJzerman; Daan van der Es
Journal:  Purinergic Signal       Date:  2020-12-12       Impact factor: 3.765

9.  FSCPX, a Chemical Widely Used as an Irreversible A₁ Adenosine Receptor Antagonist, Modifies the Effect of NBTI, a Nucleoside Transport Inhibitor, by Reducing the Interstitial Adenosine Level in the Guinea Pig Atrium.

Authors:  Tamas Erdei; Adrienn Monika Szabo; Nora Lampe; Katalin Szabo; Rita Kiss; Judit Zsuga; Csaba Papp; Akos Pinter; Andras Jozsef Szentmiklosi; Zoltan Szilvassy; Bela Juhasz; Rudolf Gesztelyi
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.